A biomarker is, according to the US National Institutes of Health, "a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention."
Biomarkers make take the form of cellular characteristics, metabolites (e.g. sugars, lipids and hormones), molecular variations, or physical features (e.g., clinical symptoms) and are assessed accordingly, via measurement, annotation, documents, and images.
Increasingly, the discovery of novel biomarkers is closely associated with the advances in molecular biology techniques that can be accessed through analysis of DNA, RNA or proteins.
We can discriminate four main types of molecular biomarkers:
Genomic biomarkers: Based on the analysis of DNA (deoxyribonucleic acid) profiles, especially the analysis of SNPs (single nucleotide polymorphisms), i.e. identification of punctual variations in genomic DNA.
Transcriptomic biomarkers: Base on the analysis of RNA expression profiles.
Proteomic biomarkers: Base on the analysis of the protein profiles.
Metabolomic biomarkers: Base on the analysis of metabolites (metabolites are the intermediates and products of metabolism).
Commercializing biomarkers is the path that a biomarker could be used in therapeutic or diagnostic. In this report mainly covers consumables, services, software of this market.
This report contains market size and forecasts of Commercializing Biomarkers in Therapeutic and Diagnostic Applications in Global, including the following market information:
Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Commercializing Biomarkers in Therapeutic and Diagnostic Applications market was valued at 22010 million in 2021 and is projected to reach US$ 30140 million by 2028, at a CAGR of 4.6% during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Consumables Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Commercializing Biomarkers in Therapeutic and Diagnostic Applications include Roche, Dako (Agilent Technologies), Merck, BD, Abbott, Genesys Biolabs (20/20GeneSystems), Affymetrix, Agendia and ALMAC, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Commercializing Biomarkers in Therapeutic and Diagnostic Applications companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Segment Percentages, by Type, 2021 (%)
- Consumables
- Services
- Software
Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Segment Percentages, by Application, 2021 (%)
- Oncology
- Cardiology
- Neurology
- Other
Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Segment Percentages, By Region and Country, 2021 (%)
- North America
- - US
- - Canada
- - Mexico
- Europe
- - Germany
- - France
- - U.K.
- - Italy
- - Russia
- - Nordic Countries
- - Benelux
- - Rest of Europe
- Asia
- - China
- - Japan
- - South Korea
- - Southeast Asia
- - India
- - Rest of Asia
- South America
- - Brazil
- - Argentina
- - Rest of South America
- Middle East & Africa
- - Turkey
- - Israel
- - Saudi Arabia
- - UAE
- - Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Commercializing Biomarkers in Therapeutic and Diagnostic Applications revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Commercializing Biomarkers in Therapeutic and Diagnostic Applications revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
- Roche
- Dako (Agilent Technologies)
- Merck
- BD
- Abbott
- Genesys Biolabs (20/20GeneSystems)
- Affymetrix
- Agendia
- ALMAC
- Arrayit
- Biocartic
- BG Medicine
- KEGG EXPRESSION Database
- Thermo Fisher
- BGI
Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market - Global Outlook and Forecast 2022-2028
Table of Contents
1 Introduction to Research & Analysis Reports
1.1 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Overall Market Size
2.1 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size: 2021 VS 2028
2.2 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Commercializing Biomarkers in Therapeutic and Diagnostic Applications Players in Global Market
3.2 Top Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Companies Ranked by Revenue
3.3 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Companies
3.4 Top 3 and Top 5 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Companies in Global Market, by Revenue in 2021
3.5 Global Companies Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product Type
3.6 Tier 1, Tier 2 and Tier 3 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Players in Global Market
3.6.1 List of Global Tier 1 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Companies
3.6.2 List of Global Tier 2 and Tier 3 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Companies
4 Market Sights by Product
4.1 Overview
4.1.1 by Type - Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size Markets, 2021 & 2028
4.1.2 Consumables
4.1.3 Services
4.1.4 Software
4.2 By Type - Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue & Forecasts
4.2.1 By Type - Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, 2017-2022
4.2.2 By Type - Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, 2023-2028
4.2.3 By Type - Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Market Share, 2017-2028
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size, 2021 & 2028
5.1.2 Oncology
5.1.3 Cardiology
5.1.4 Neurology
5.1.5 Other
5.2 By Application - Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue & Forecasts
5.2.1 By Application - Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, 2017-2022
5.2.2 By Application - Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, 2023-2028
5.2.3 By Application - Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Market Share, 2017-2028
6 Sights by Region
6.1 By Region - Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size, 2021 & 2028
6.2 By Region - Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue & Forecasts
6.2.1 By Region - Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, 2017-2022
6.2.2 By Region - Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, 2023-2028
6.2.3 By Region - Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Market Share, 2017-2028
6.3 North America
6.3.1 By Country - North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, 2017-2028
6.3.2 US Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size, 2017-2028
6.3.3 Canada Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size, 2017-2028
6.3.4 Mexico Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size, 2017-2028
6.4 Europe
6.4.1 By Country - Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, 2017-2028
6.4.2 Germany Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size, 2017-2028
6.4.3 France Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size, 2017-2028
6.4.4 U.K. Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size, 2017-2028
6.4.5 Italy Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size, 2017-2028
6.4.6 Russia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size, 2017-2028
6.4.7 Nordic Countries Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size, 2017-2028
6.4.8 Benelux Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size, 2017-2028
6.5 Asia
6.5.1 By Region - Asia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, 2017-2028
6.5.2 China Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size, 2017-2028
6.5.3 Japan Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size, 2017-2028
6.5.4 South Korea Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size, 2017-2028
6.5.5 Southeast Asia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size, 2017-2028
6.5.6 India Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size, 2017-2028
6.6 South America
6.6.1 By Country - South America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, 2017-2028
6.6.2 Brazil Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size, 2017-2028
6.6.3 Argentina Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size, 2017-2028
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, 2017-2028
6.7.2 Turkey Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size, 2017-2028
6.7.3 Israel Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size, 2017-2028
6.7.4 Saudi Arabia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size, 2017-2028
6.7.5 UAE Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size, 2017-2028
7 Players Profiles
7.1 Roche
7.1.1 Roche Corporate Summary
7.1.2 Roche Business Overview
7.1.3 Roche Commercializing Biomarkers in Therapeutic and Diagnostic Applications Major Product Offerings
7.1.4 Roche Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue in Global Market (2017-2022)
7.1.5 Roche Key News
7.2 Dako (Agilent Technologies)
7.2.1 Dako (Agilent Technologies) Corporate Summary
7.2.2 Dako (Agilent Technologies) Business Overview
7.2.3 Dako (Agilent Technologies) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Major Product Offerings
7.2.4 Dako (Agilent Technologies) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue in Global Market (2017-2022)
7.2.5 Dako (Agilent Technologies) Key News
7.3 Merck
7.3.1 Merck Corporate Summary
7.3.2 Merck Business Overview
7.3.3 Merck Commercializing Biomarkers in Therapeutic and Diagnostic Applications Major Product Offerings
7.3.4 Merck Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue in Global Market (2017-2022)
7.3.5 Merck Key News
7.4 BD
7.4.1 BD Corporate Summary
7.4.2 BD Business Overview
7.4.3 BD Commercializing Biomarkers in Therapeutic and Diagnostic Applications Major Product Offerings
7.4.4 BD Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue in Global Market (2017-2022)
7.4.5 BD Key News
7.5 Abbott
7.5.1 Abbott Corporate Summary
7.5.2 Abbott Business Overview
7.5.3 Abbott Commercializing Biomarkers in Therapeutic and Diagnostic Applications Major Product Offerings
7.5.4 Abbott Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue in Global Market (2017-2022)
7.5.5 Abbott Key News
7.6 Genesys Biolabs (20/20GeneSystems)
7.6.1 Genesys Biolabs (20/20GeneSystems) Corporate Summary
7.6.2 Genesys Biolabs (20/20GeneSystems) Business Overview
7.6.3 Genesys Biolabs (20/20GeneSystems) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Major Product Offerings
7.6.4 Genesys Biolabs (20/20GeneSystems) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue in Global Market (2017-2022)
7.6.5 Genesys Biolabs (20/20GeneSystems) Key News
7.7 Affymetrix
7.7.1 Affymetrix Corporate Summary
7.7.2 Affymetrix Business Overview
7.7.3 Affymetrix Commercializing Biomarkers in Therapeutic and Diagnostic Applications Major Product Offerings
7.7.4 Affymetrix Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue in Global Market (2017-2022)
7.7.5 Affymetrix Key News
7.8 Agendia
7.8.1 Agendia Corporate Summary
7.8.2 Agendia Business Overview
7.8.3 Agendia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Major Product Offerings
7.8.4 Agendia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue in Global Market (2017-2022)
7.8.5 Agendia Key News
7.9 ALMAC
7.9.1 ALMAC Corporate Summary
7.9.2 ALMAC Business Overview
7.9.3 ALMAC Commercializing Biomarkers in Therapeutic and Diagnostic Applications Major Product Offerings
7.9.4 ALMAC Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue in Global Market (2017-2022)
7.9.5 ALMAC Key News
7.10 Arrayit
7.10.1 Arrayit Corporate Summary
7.10.2 Arrayit Business Overview
7.10.3 Arrayit Commercializing Biomarkers in Therapeutic and Diagnostic Applications Major Product Offerings
7.10.4 Arrayit Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue in Global Market (2017-2022)
7.10.5 Arrayit Key News
7.11 Biocartic
7.11.1 Biocartic Corporate Summary
7.11.2 Biocartic Business Overview
7.11.3 Biocartic Commercializing Biomarkers in Therapeutic and Diagnostic Applications Major Product Offerings
7.11.4 Biocartic Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue in Global Market (2017-2022)
7.11.5 Biocartic Key News
7.12 BG Medicine
7.12.1 BG Medicine Corporate Summary
7.12.2 BG Medicine Business Overview
7.12.3 BG Medicine Commercializing Biomarkers in Therapeutic and Diagnostic Applications Major Product Offerings
7.12.4 BG Medicine Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue in Global Market (2017-2022)
7.12.5 BG Medicine Key News
7.13 KEGG EXPRESSION Database
7.13.1 KEGG EXPRESSION Database Corporate Summary
7.13.2 KEGG EXPRESSION Database Business Overview
7.13.3 KEGG EXPRESSION Database Commercializing Biomarkers in Therapeutic and Diagnostic Applications Major Product Offerings
7.13.4 KEGG EXPRESSION Database Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue in Global Market (2017-2022)
7.13.5 KEGG EXPRESSION Database Key News
7.14 Thermo Fisher
7.14.1 Thermo Fisher Corporate Summary
7.14.2 Thermo Fisher Business Overview
7.14.3 Thermo Fisher Commercializing Biomarkers in Therapeutic and Diagnostic Applications Major Product Offerings
7.14.4 Thermo Fisher Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue in Global Market (2017-2022)
7.14.5 Thermo Fisher Key News
7.15 BGI
7.15.1 BGI Corporate Summary
7.15.2 BGI Business Overview
7.15.3 BGI Commercializing Biomarkers in Therapeutic and Diagnostic Applications Major Product Offerings
7.15.4 BGI Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue in Global Market (2017-2022)
7.15.5 BGI Key News
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
List of Tables
Table 1. Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Opportunities & Trends in Global Market
Table 2. Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Drivers in Global Market
Table 3. Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Restraints in Global Market
Table 4. Key Players of Commercializing Biomarkers in Therapeutic and Diagnostic Applications in Global Market
Table 5. Top Commercializing Biomarkers in Therapeutic and Diagnostic Applications Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Share by Companies, 2017-2022
Table 8. Global Companies Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product Type
Table 9. List of Global Tier 1 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type - Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application - Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region - Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, (US$, Mn), 2023-2028
Table 30. Roche Corporate Summary
Table 31. Roche Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product Offerings
Table 32. Roche Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (US$, Mn), (2017-2022)
Table 33. Dako (Agilent Technologies) Corporate Summary
Table 34. Dako (Agilent Technologies) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product Offerings
Table 35. Dako (Agilent Technologies) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (US$, Mn), (2017-2022)
Table 36. Merck Corporate Summary
Table 37. Merck Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product Offerings
Table 38. Merck Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (US$, Mn), (2017-2022)
Table 39. BD Corporate Summary
Table 40. BD Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product Offerings
Table 41. BD Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (US$, Mn), (2017-2022)
Table 42. Abbott Corporate Summary
Table 43. Abbott Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product Offerings
Table 44. Abbott Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (US$, Mn), (2017-2022)
Table 45. Genesys Biolabs (20/20GeneSystems) Corporate Summary
Table 46. Genesys Biolabs (20/20GeneSystems) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product Offerings
Table 47. Genesys Biolabs (20/20GeneSystems) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (US$, Mn), (2017-2022)
Table 48. Affymetrix Corporate Summary
Table 49. Affymetrix Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product Offerings
Table 50. Affymetrix Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (US$, Mn), (2017-2022)
Table 51. Agendia Corporate Summary
Table 52. Agendia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product Offerings
Table 53. Agendia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (US$, Mn), (2017-2022)
Table 54. ALMAC Corporate Summary
Table 55. ALMAC Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product Offerings
Table 56. ALMAC Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (US$, Mn), (2017-2022)
Table 57. Arrayit Corporate Summary
Table 58. Arrayit Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product Offerings
Table 59. Arrayit Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (US$, Mn), (2017-2022)
Table 60. Biocartic Corporate Summary
Table 61. Biocartic Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product Offerings
Table 62. Biocartic Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (US$, Mn), (2017-2022)
Table 63. BG Medicine Corporate Summary
Table 64. BG Medicine Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product Offerings
Table 65. BG Medicine Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (US$, Mn), (2017-2022)
Table 66. KEGG EXPRESSION Database Corporate Summary
Table 67. KEGG EXPRESSION Database Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product Offerings
Table 68. KEGG EXPRESSION Database Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (US$, Mn), (2017-2022)
Table 69. Thermo Fisher Corporate Summary
Table 70. Thermo Fisher Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product Offerings
Table 71. Thermo Fisher Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (US$, Mn), (2017-2022)
Table 72. BGI Corporate Summary
Table 73. BGI Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product Offerings
Table 74. BGI Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (US$, Mn), (2017-2022)
List of Figures
Figure 1. Commercializing Biomarkers in Therapeutic and Diagnostic Applications Segment by Type in 2021
Figure 2. Commercializing Biomarkers in Therapeutic and Diagnostic Applications Segment by Application in 2021
Figure 3. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Overview: 2020
Figure 4. Key Caveats
Figure 5. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue in 2021
Figure 8. By Type - Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Market Share, 2017-2028
Figure 9. By Application - Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Market Share, 2017-2028
Figure 10. By Region - Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Market Share, 2017-2028
Figure 11. By Country - North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Market Share, 2017-2028
Figure 12. US Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Market Share, 2017-2028
Figure 16. Germany Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, (US$, Mn), 2017-2028
Figure 17. France Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Market Share, 2017-2028
Figure 24. China Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, (US$, Mn), 2017-2028
Figure 28. India Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Market Share, 2017-2028
Figure 30. Brazil Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Market Share, 2017-2028
Figure 33. Turkey Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue, (US$, Mn), 2017-2028
Figure 37. Roche Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Dako (Agilent Technologies) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Merck Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. BD Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Abbott Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Genesys Biolabs (20/20GeneSystems) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Affymetrix Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Agendia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. ALMAC Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 46. Arrayit Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 47. Biocartic Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 48. BG Medicine Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 49. KEGG EXPRESSION Database Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 50. Thermo Fisher Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 51. BGI Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Global Biomarkers Market Growth (Status and Outlook) 2024-2030
Published: 04-Jan-2024 Price: US 3660 Onwards Pages: 94
According to our LPI (LP Information) latest study, the global Biomarkers market size was valued at US$ 61570 million in 2023. With growing demand in downstream market, the Biomarkers is forecast to a readjusted size of US$ 165240 million by 2030 with a CAGR of 15.1% during review period.
The research report highlights the growth potential of the global Biomarkers market. Biomarkers are expected to show stable growth in the future market. However, product differentiation, reducing costs,......
Global Biomarker (Medicine) Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
Published: 04-Jan-2024 Price: US 3380 Onwards Pages: 114
Market Overview of Global Biomarker (Medicine) market:
According to our latest research, the global Biomarker (Medicine) market looks promising in the next 5 years. As of 2022, the global Biomarker (Medicine) market was estimated at USD 54332.95 million, and it's anticipated to reach USD 82760.29 million in 2028, with a CAGR of 7.27% during the forecast years.
Biomarkers (short for biological markers) are biological measures of a biological state. By definition, a biomarker i......
Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Growth (Status and Outlook) 2024-2030
Published: 04-Jan-2024 Price: US 3660 Onwards Pages: 131
According to our LPI (LP Information) latest study, the global Commercializing Biomarkers in Therapeutic and Diagnostic Applications market size was valued at US$ 20920 million in 2023. With growing demand in downstream market, the Commercializing Biomarkers in Therapeutic and Diagnostic Applications is forecast to a readjusted size of US$ 29400 million by 2030 with a CAGR of 5.0% during review period.
The research report highlights the growth potential of the global Commercializing Biom......
Global Biomarkers Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
Published: 05-Dec-2023 Price: US 3380 Onwards Pages: 100
Market Overview of Global Biomarkers market:
According to our latest research, the global Biomarkers market looks promising in the next 5 years. As of 2022, the global Biomarkers market was estimated at USD 76755.97 million, and it's anticipated to reach USD 184776.75 million in 2028, with a CAGR of 15.77% during the forecast years.
This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis of the global Biomarkers market, with a......
Global Biomarker Technology Market Research Report 2023
Published: 01-Dec-2023 Price: US 2900 Onwards Pages: 86
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Biomarker Technology market with multiple angles, which provides sufficient supports to readers' strategy and decision making.
By Company
- Abbott Laboratories
- Quanterix
- Bio-Rad Laboratories
- Epigenomics
- Agilent Technologies
- Johnson & Johnson
- Qiagen
- Roche Ho......
Global Renal Biomarkers Market Research Report 2023
Published: 01-Dec-2023 Price: US 2900 Onwards Pages: 99
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Renal Biomarkers market with multiple angles, which provides sufficient supports to readers' strategy and decision making.
By Company
- Abbott Diagnostics
- F. Hoffmann-La Roche
- Beckman Coulter
- Siemens Healthcare Diagnostics
- Thermo Fisher Scientific
- Astute Medical
- Bio......
Global Central Nervous System (CNS) Biomarkers Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
Published: 30-Nov-2023 Price: US 3380 Onwards Pages: 114
Market Overview of Global Central Nervous System (CNS) Biomarkers market:
According to our latest research, the global Central Nervous System (CNS) Biomarkers market looks promising in the next 5 years. As of 2022, the global Central Nervous System (CNS) Biomarkers market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years.
An overview of the global market for central nervous system (CNS) biomarke......
Global Cancer Biomarker Market Research Report 2023
Published: 13-Nov-2023 Price: US 2900 Onwards Pages: 109
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Cancer Biomarker market with multiple angles, which provides sufficient supports to readers' strategy and decision making.
By Company
- Thermo Fisher Scientific
- Bio-Rad Laboratories
- Roche Diagnostics
- Qiagen
- Illumina
- GE Healthcare
- Agilent Technologies
- Biomér......
Biomarker Collaboration and Licensing Deals 2016-2023
Published: 01-Nov-2023 Price: US 3995 Onwards Pages: 300
Biomarker Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the biomarker deals entered into by the worlds leading biopharma companies.
Fully revised and updated, the report provides details of biomarker deals from 2016 to 2023.
The report provides a detailed understanding and analysis of how and why companies enter biomarker deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercializ......
SERVICES
Value for Money
We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
Ever Growing Inventory
Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
One Stop Solution
Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
Dedicated Client Engagement
Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
Saving Time and Efforts
Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
Payment Flexibility
Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
Post-Purchase Research Support
Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements.
Subscription Offers & Packages (Get in touch with us for more details -
[email protected] / +1 888 391 5441 )
- Ad Hoc
-
- Pay - as - you - go / Bucket Subscriptions
- Fixed Cost for #of reports
- Customize / Personalize as per your needs
